InsidersTradesSigma
차바이오텍 Stock: price and directors' dealings · South Korea · DART (FSS)
Follow the 차바이오텍 share price and the full directors' dealings record of the company, a listed equity based in South Korea. Shares trade on KR KR, under the oversight of DART (FSS). Operating in the Health Care sector, 차바이오텍 has published 94 public disclosures. Market capitalisation: €826.5bn. The latest transaction was filed on 22 May 2026 (Purchase). Among the most active insiders: 차광렬. The full history is accessible without an account.
94
Insider Decl.
n/a
Thresholds
n/a
13 ops.
Buy Volume
€846,999
11 ops.
Sell Volume
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 26,390 of 28,134 companies
17.3
score / 100
Value11
Quality24
FCF yld-26%
Earn yld-13%
EV/EBITDA·
ROE-14%
Gross mgn29%
Net mgn-8.7%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 22 May 2026
Declarations94 total
25 of 94 declarations
About 차바이오텍
차바이오텍 is a company specializing in the health and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative therapies and biopharmaceutical solutions.